GSK's $1.4B Aiolos Bio Acquisition Bolsters Asthma Pipeline
TL;DR
GSK has announced its acquisition of Aiolos Bio, a clinical-stage asthma drugmaker, for an upfront payment of $1 billion with the potential for an additional $400 million based on meeting milestones. This purchase comes just three months after Aiolos Bio emerged as a startup with a significant private financing round of $245 million, making it one of the fastest startup unveilings to buyout journeys in recent biotech memory.
- GSK to buy asthma biotech Aiolos Bio for up to $1.4B three months after startup emerged: #JPM24 Endpoints News
- GSK, moving fast to buy Aiolos, pays $1B to challenge Amgen, AstraZeneca for asthma market FierceBiotech
- GSK to buy asthma-drug developer for up to $1.4 billion in pipeline push MarketWatch
- GSK Puts $1.4B on the Line in Aiolos Acquisition to Boost Asthma Pipeline BioSpace
- GSK boosts respiratory portfolio with $1.4 bln Aiolos Bio deal Reuters
Want the full story? Read the original reporting
Read on Endpoints News